Table 3. Single-Rate Pooled Analysis of OS and PFS for Proton Therapy.
| Follow-up, y | Treatment modality | Stage | Overall | Publication bias | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neoadjuvant, HR (95% CI) | Radical | Mixeda | III-IV (<50%) | III-IV (≥50%) | |||||||||
| HR (95% CI) | I2, % | HR (95% CI) | I2, % | HR (95% CI) | I2, % | HR (95% CI) | I2, % | HR (95% CI) | I2, % | ||||
| OS | |||||||||||||
| 1 | 0.82 (0.66-0.94)b | 0.92 (0.85-0.97) | 78.1 | 0.84 (0.77-0.90) | 8.4 | 0.96 (0.88-1.00) | 72.1 | 0.85 (0.80-0.90) | 45.4 | 0.89 (0.84-0.93) | 69.3 | NAc | |
| 2 | 0.70 (0.52-0.85)b | 0.77 (0.67-0.85) | 79.7 | 0.58 (0.47-0.68) | 42.6 | 0.85 (0.74-0.93) | 68.8 | 0.64 (0.59-0.68) | 6.6 | 0.71 (0.63-0.78) | 75.5 | NAc | |
| 3 | NAd | 0.68 (0.55-0.80) | 87.1 | 0.50 (0.41-0.59)b | 0.78 (0.63-0.91) | 80.8 | 0.53 (0.48-0.58) | 0 | 0.63 (0.53-0.73) | 81.9 | NAc | ||
| 5 | NAe | 0.58 (0.46-0.70) | 84.6 | NAd | 0.71 (0.64-0.79) | 0 | 0.45 (0.39-0.50) | 0 | 0.56 (0.46-0.67) | 82 | Nonef | ||
| PFS | |||||||||||||
| 1 | NAe | 0.65 (0.48-0.82) | 88.9 | 0.64 (0.49-0.79) | 50.5 | NAd | 0.61 (0.53-0.68) | 45.4 | 0.65 (0.53-0.77) | 83.3 | Nonef | ||
| 2 | NAe | 0.57 (0.45-0.70) | 73.8 | 0.54 (0.43-0.65) | 0 | NAd | 0.52 (0.46-0.57) | 0 | 0.56 (0.48-0.64) | 52.1 | Nonef | ||
| 3 | NAe | 0.49 (0.38-0.60)b | NAd | NA | NAd | 0.44 (0.38-0.51) | 85.4 | 0.48 (0.40-0.56) | 45.0 | NAc | |||
| 5 | NAe | 0.43 (0.31-0.55)b | NAd | NA | NAd | 0.38 (0.32-0.44)b | 0.42 (0.34-0.51) | 54.2 | NAc | ||||
Abbreviations: NA, not applicable or not evaluable; OS, overall survival; PFS, progression-free survival.
a
Mixed indicates both neoadjuvant and radical treatments were used.
b
Included 3 studies or fewer (after double-arcsine transformations), so the I2 is not shown.
c
After double-arcsine transformations (did not perform publication bias test).
d
Represents only 1 study.
e
Represents no study.
f
Represents publication bias detected by funnel plot (because included <10 studies).